The aim of this study was to analyze the role of radiotherapy in treatment of brain metastases (BM) from breast cancer in the context of modern local therapy modalities, current systemic treatment options and prognostic factors. We retrospectively analyzed 86 consecutive female patients (treatment period 2000 to 2010) with BM from breast cancer, who were treated with radiotherapy at a single centre. Patient and treatment characteristics were registered, survival data calculated and compared between subgroups. All patients received whole-brain radiotherapy (WBRT) with a median dose of 36 Gy (3-46 Gy). 19 patients were treated with an additional boost (fractionated schemes and/or radiosurgery). The median overall survival from the start of WBRT was 4.1 months. Patients receiving WBRT + boost survived significantly longer than patients treated with WBRT alone (19.7 vs. 3.1 months, p=0.03). Radiotherapy influences survival of patients with BM from breast cancer. Particularly the implementation of boost treatment after WBRT in selected patients seems to extend survival time.